Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Non-Current Liabilities (2019 - 2025)

Karyopharm Therapeutics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $329.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 18.8% year-over-year to $329.0 million; the TTM value through Dec 2025 reached $329.0 million, up 18.8%, while the annual FY2025 figure was $329.0 million, 18.8% up from the prior year.
  • Total Non-Current Liabilities reached $329.0 million in Q4 2025 per KPTI's latest filing, down from $351.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $375.7 million in Q4 2023 to a low of $237.2 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $285.0 million, with a median of $265.2 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 55.16% in 2023, then dropped 29.86% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $252.0 million in 2021, then dropped by 3.92% to $242.1 million in 2022, then surged by 55.16% to $375.7 million in 2023, then fell by 26.28% to $276.9 million in 2024, then rose by 18.8% to $329.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Total Non-Current Liabilities are $329.0 million (Q4 2025), $351.4 million (Q3 2025), and $270.3 million (Q2 2025).